Contineum Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Contineum Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $19.01M.
- Contineum Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $107.87M.
- Contineum Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00.
- Contineum Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $0.00.
- Contineum Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $107.87M.
- Contineum Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $0.00.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $19.01M 10-Q · filed 2025-10-30 | |
| 2024-12-31 | $107.87M 10-K · filed 2025-03-06 | |
| 2024-06-30 | $107.87M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |